Foley  

Sica  

Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease
Robert N. Foley, MD, and Domenic A. Sica, MD. (ASN Renal Week, 2006). Foley: How are classic and novel risk factors related to outcome in CKD patients as well as in dialysis patients? What can we learn from Framingham data? From NHANES? Which of the classical risk factors works in the opposite direction when GFR is low? To what extent have patients with mild-moderate CKD been excluded from the major cardiovascular trials? What can we learn from analysis of these subsets? How do the observational data differ from randomized, controlled trials?
Sica: How are the pathogenses of CKD and CVD (cardiovascular disease) related? Where do both impact the RAS (renin-angiotensin system)? How does ACE inhibition affect different parts of the cardiovascular system? What conclusions can we draw from AASK? How can we rationally choose drugs from different classes to treat hypertension? How should different calcium-blockers and ACE inhibitors be used in CKD? How do ACE inhibitors and ARBs compare? (ASN Renal Week Official Symposium, 2006).
(more...)



Townsend  

Secondary Hypertension, including Chronic Kidney Disease
Ray Townsend, MD. (ASN Board Review Course, 2006). Townsend: Renin system activation, mineralocorticoid excess states, pheo, aortic coarctation, and primary renal disease are the main types. What is the best means to diagnose renovascular HTN? What are less common types of RV HTN? How do we approach low renin, high aldo HTN? What are diagnostic criteria (aldo/renin ratios, urinary aldos, etc.), and what are the treatment options besides surgery? How do we approach Cushing's, pheo, and hyper- and hypothyroidism and HTN? What are the main genetic disorders? Liddle, GRH, activating MR receptor mutations, and 11-beta-hydroxysteroid dehydrogenase? What is Gordon's syndrome? What are the main drug-induced causes, including anti-angiogenesis agents? What's new in treating HTN associated with CKD?
(more...)



White  

Calhoun  

Cosio  

Resistant Hypertension: Reducing Cardiovascular Events
(ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
White: During introductory remarks, two cases of resistant hypertension are presented to set the stage. A young woman who works in a hospital on 3 drugs with BP 160/100, and an elderly retiree who finds that his AM BP is quite elevated on home monitoring. Calhoun: What is the prevalence of primarly aldosteronism in hypertensives, and how does this depend on the resistance of hypertension to treatment? What percent of hypertension is low-renin. To what degree does resistant hypertension respond to aldosterone blockers, and does this depend on aldosterone excretion rates? How are high-aldosterone hypertensives different from those with normal aldo levels in terms of endothelial dilation, LVH, and other measures? How can aldosterone blockade as well as salt intake modify endothelial vasodilatory capacity and LVH? White: In resistant hypertension, what other drugs can we use? How do CCB/ACE combos compare to BB/D? What dose of diuretic should be added to an ACE/ARB regimen? Is ARB half-life important? What are new drugs on the horizon? Cosio: What should target LDL-C (LDL cholesterol) levels be for CKD patients? How do CV risk factors cluster in CKD patients? Which dyslipidemias are associated with increased risk? How can one treat low HDL-cholesterol? What did the ALERT and 4-D trials show? How do we explain the negative results of the 4-D trial?
(more...)
Updated: July 03, 2008 (J03)
J03 Statins spur glial progenitor cells to develop into oligodendrocytes.
J01 Caffeine intake increases rate at which muscle replenishes glycogen stores after exercise.
J01 Doxycycline-inhibitable protease activity increased in SHR rats; this also may explain various aspects of metabolic syndrome.
J30 AHA publishes cookbook focusing on healthy soul food recipes
J30 Sudden hearing loss associated with increased risk of future stroke.
J30 AHA launches hearthub.org, a website for patients.
J30 Prevalence of silent cerebral infarction in healthy (mean age 62) people at 11% in MRI study.
J26 Fructose, but not glucose, increases visceral adipose tissue and triglycerides, and lower insulin sensitivity.
J25 African Americans excrete less potassium in the urine, and it's not all due to dietary intake.
J25 Obesity drug rimonabant approved for NHS use in England and Wales.
J23 New source of cardiac stem cells found in the epicardium
J17 Big breakfast diet more effective than low-carb diet in maintaining weight loss.
J12 XBP1, stimulated by a high-carb diet, may be a new target for treatment of dyslipidemias.
J12 A subgroup of retinal cells linked to circadian cycle resetting and insomnia.
J12 FDA approves generic form of ramipril made by Lupin pharmaceuticals.
Industry Advances Emphasis
archive
Secondary Hypertension, including Chronic Kidney Disease ASN Board Review 2006
Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease ASN Renal Week 2006
Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients (Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD) ADC 2006 (audio only)
Emerging New Agents in Diabetic Kidney Disease (Lewis) ASN 2005 Renal Week
Coronary Angioplasty and Stenting: Indications and Results (Williams) ASN 2005 Renal Week
Webcasts from the ISH 2006 meeting in Fukuoka, Japan, October, 2006 (ISH 2006) ADC 2006 (audiofiles)
Blood Pressure on Dialysis (Kalantar-Zadeh, Reams, Misra, Sherman, Charra) ADC 2006 (audiofiles)
Uric acid as a Uremic Toxin (Ikizler, Nakagawa) RRI 2006, Part 2 (handouts)
Sodium as a Uremic Toxin (Ritz) RRI 2006, Part 2 (handouts)
Kidneys, Hearts, Hormones, Immunomodulators and More: Complex Systems Requiring Integrated Understandings (Adeera Levin) RRI 2006, Part 2 (handouts)
Cardiovascular Disease Causes and Consequences of Sympathetic Hyperactivity in CKD (Kotanko) RRI 2006, Part 3 (handouts)
Dry Weight Assessment and Rebound (Kuhlmann, Greenwood) RRI 2006, Part 3 (handouts)
Resistant Hypertension: Reducing Cardiovascular Events (White, Calhoun, Cosio) ASN Renal Week 2005
Hypertensive Urgencies and Emergencies: Clinical Syndromes And Therapy (Textor) ASN Renal Week 2005
Pathogenic Mechanisms of Ischemic Nephropathy (Lerman, Navar, Wilcox, Julliard) ASN Renal Week 2005 (audiofiles)
Inflammation, Dyslipidemia and the Kidney (Massy, Tonelli, Danovitch, Kasiske, Landray) ASN Renal Week 2005 (audiofiles)
Refractory Hypertension: Pathogenesis, Diagnosis and Therapy (Townsend, Norris, Sica) ASN Renal Week 2005 (audiofiles)
Childhood Hypertension: The View in 2005 (Flynn, Bertram, Portman) ASN Renal Week 2005 (audiofiles)
Genetic Hypertension and the Cortical Collecting Duct (CCD): What Every Nephrologist Must Know! (Ferrari, Luft, Geller, Auchus) ASN Renal Week 2005 (audiofiles)
Kidney-Heart Interactions (Pfeffer, Ritz, Burnett) ASN Renal Week 2005 (audiofiles)
Aldosterone, Resistant Hypertension and Target Organ Injury (Calhoun, Goodfriend, Weber, Geller) ASN Renal Week 2005 (audiofiles)
Cardiovascular Risk Factors and Renal Disease (Vaziri, Bostom, Hsueh) ASN Renal Week 2005 (audiofiles)
Emerging Concepts in Cardiovascular Disease (Stenvinkel, Moe) ASN Renal Week 2005 (audiofiles)
Treatment of Hypertension in CKD (Adler, Toto, Levin, Peixoto, Weir) ASN Renal Week 2005 (audiofiles)
Influence of Lifestyle on Hypertension, CKD, and CVD (Kramer, Tuttle) ASN Renal Week 2005 (audiofiles)
Secondary Hypertension (Gomez-Sanchez, Dworkin, Toto) ASN Renal Week 2005 (audiofiles)
The Heart on Dialysis (Part 1) (Kalantar-Zadeh, Aggarwal, Kopple, Saran) ADC 2005 (audiofiles)
Hypertension, CKD, and CVD Risks (Moe, London, Sarnak) ADC 2005 (audiofiles)
Hypertension in Special Populations (Portman, Izzo, Norris, August, Sarnak) ADC 2005 (audiofiles)
The Heart on Dialysis (Part 2) (Beddhu, Amerling, Sherman, Misra, Herzog) ADC 2005 (audiofiles)
Controlling Volume Status and Blood Pressure in PD Patients (Faber, Selgas, Rippe) ADC 2005 (audiofiles)
The Unexplained Relationship of Blood Pressure to Survival in the Dialysis Patient: A New Explanation (Saran) RRI 2005 (audiofiles)
The Impact of Post-Dialysis Weight on Patient Outcomes in Hemodialysis (Charra) RRI 2005 (audiofiles)
Renin-Angiotensin System Actions and Interactions in CKD (Anderson) ASN 2004
New Insights in the Pathogenesis of Uric Acid Nephrolithiasis (Sakhaee) ASN 2004
When and How to Use the Selective Aldosterone Receptor Antagonists to Optimize Cardiorenal Event Reduction (Bakris) ASN 2004
Secondary Hypertension Including Chronic Kidney Disease (Toto) ASN Board Review 2004
Uric acid, the kidney, and the pathogenesis of hypertension. Two parts. (Johnson) ASN Renal Week
Therapy in ischemic nephropathy : A data based approach (Textor) ASN Renal Week
Role of the sympathetic nervous system in the control of hypertension (Campese) ASN 2002 Renal Week
Renal autoregulation and hypertension injury: Do all agents that lower blood pressure protect the kidney? (Griffin) ASN 2002 Renal Week
Ideal actions of anti-hypertensive drugs (Ruilope) ASN 2002 Renal Week
The Malnutrition - Inflammation - Atherosclerosis or MIA syndrome (Stenvinkel) ASN 2002 Renal Week
Microalbuminuria: The kidney's message about the systemic vasculature (Tuttle) ASN 2002 Renal Week
Treatment of hypertension in renal parenchymal disease (Bakris) ASN 2002 Board Review Course
How to reduce CV risk in the patient with chronic kidney disease (Culleton) NKF 2002 Spring Meeting
How do calcium/phosphorus abnormalities contribute to CV risk? (Goodman) NKF 2002 Spring Meeting
Current concepts in the diagnosis and management of pediatric hypertension (Portman) NKF 2002 Spring Meeting
Aldosterone, salt and cardiac fibrosis (Funder)

Should patients with venous thromboembolism be screened for thrombophilia? Am J Med (Jun 2008)
Lipid abnormalities and cardiovascular risk in renal disease J Am Soc Nephrol (Jun 2008)
Debate: Weight loss and blood pressure control (Pro) vs. Dietary therapy for obesity: an emperor with no clothes (Con) Hypertens (Jun 2008)
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities Circulation (May 2008)
Sensing tension: epithelial sodium channel/acid-sensing ion channel proteins in cardiovascular homeostasis Hypertens (2008)
Pleiotropic effects of telmisartan: still more to come? J Hypertens (May 2008)
Prevention of heart failure: a scientific statement from the American Heart Association Councils Circulation (May 2008)
Efficacy and safety of fondaparinux and enoxaparin for acute coronary syndromes in CKD Am J Kidney Dis (May 2008)
Targeting proteinuria as a valid surrogate for individualized kidney protective therapy Am J Kidney Dis (May 2008)
Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabet Care (Apr 2008)
Effect of the Italian smoking ban on population rates of acute coronary events Circulation (Mar 2008)
Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients http://www.hdcn.net/pdf/asn/santos.pdf
Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension Kidney Int (Mar 2008)
Systolic hypertension in the elderly: addressing an unmet need Am J Med (Mar 2008)
Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease Am J Nephrol (Mar 2008)
WNK kinases and renal sodium transport in health and disease: an integrated view Hypertens (Mar 2008)
Hyperglycemia and acute coronary syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation (Mar 2008)
Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease Am J Nephrol (Mar 2008)
Association between obesity and kidney disease: A systematic review and meta-analysis Kidney Int (Jan 2008)
Beta-blockade in chronic dialysis patients Semin Dial (Feb 2008)
Mechanisms of vascular calcification in chronic kidney disease J Am Soc Nephrol (Feb 2008)
Aldosterone and vascular inflammation Hypertens (Feb 2008
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease Nephrol Dial Transplant (Feb 2008)
Adiponectin, cardiovascular function, and hypertension Hypertens (Jan 2008)
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention Circulation (Jan 2008)
Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient Hemodial Int (Jan 2008)
Atheroembolic renal disease: A silent masquerader Kidney Int (Jan 2008)
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio (Hood SJ et al) Circulation (Jul 07)
A different approach to resistant hypertension (Hirsch S) Cleveland Clinic J Med (Jun 07)
Intensive versus moderate blood-pressure control in normotensive patients with type 2 diabetes (Briggs J) NCPN Jun 07
Controveries in renal artery stenosis: A review by the American Society of Nephrology Advisory Group on Hypertension (Levin et al) Am J Nephrol 04-07
Controveries in renal artery stenosis: A review by the American Society of Nephrology Advisory Group on Hypertension (Levin A et al) Am J Nephrol (04-2007)
Lipoprotein metabolism and lipid management in chronic kidney disease JASN 04-07
ACCF/AHA 2007 Clinical Expert Consensus Document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation (02-07)
Aldosterone and Cardiovascular Disease. Smoke and Fire (Calhoun). Circulation 12-06
Effectiveness of Management Strategies for Renal Artery Stenosis: A Systematic Review (Balk et al) Annals Intern Med 12-06
Physical Activity Intervention Studies: What We Know and What We Need to Know (AHA) Circulation 12-06
Angiotensin-converting enzyme-2 (ACE-2) - a new player in the genesis of glomerular injury? (Comment by Ritz on paper by Oudit et al) JASN 10-06
Obesity: Growing Impact on CKD (McGill, Furth, Kaskel) Adv Chronic Kidney Dis 10-06
Management of dyslipidemias in patients with diabetes and chronic kidney disease (Molitch). CJASN 09-06
HYPERTENSION GUIDELINES
K-DOQI Lipid Guidelines
JNC 7
HTN in Pregnancy
ADA Clinical Practice Recs
Canadian Lifestyle Guidelines
Salt Reduction Guide
DASH Diet Facts
Guidelines.gov
Renovascular HTN (Nuc Med)
HDCN Topic Pages (KEY)
Ambulatory BP Monitoring
Arm Cuff Measurement
ACEI, AII Blockers
Beta Blockers
Ca Antagonists
Beta Blockers
Heart in HTN
Kidney in HTN
Genetics
Hormonal Physiology
Inflammatory Syndrome
Salt Sensitivity
Outcomes
Elderly
Endocrine
Syndrome X, Diabetes
Lipid Disorders
Smoking
Renovascular
HTN in Women
PATIENT LINKS, TRIALS
American Heart Assoc
National Stroke Assoc
NHLBI
Clinical Trials (NIH)
CV Risk Calculator

Dr. Carmine Zoccali, M.D.
Postgraduate Professor of Nephrology, Director, Center for Clinical Physiology, Renal Diseases and Hypertension of the Italian Research Council, Reggio Calabria, Italy (European Editor)